These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
184 related articles for article (PubMed ID: 29651569)
1. External radiation exposure, excretion, and effective half-life in Kurth J; Krause BJ; Schwarzenböck SM; Stegger L; Schäfers M; Rahbar K EJNMMI Res; 2018 Apr; 8(1):32. PubMed ID: 29651569 [TBL] [Abstract][Full Text] [Related]
2. Evaluation of radiation safety in (177)Lu-PSMA therapy and development of outpatient treatment protocol. Demir M; Abuqbeitah M; Uslu-Beşli L; Yıldırım Ö; Yeyin N; Çavdar İ; Vatankulu B; Gündüz H; Kabasakal L J Radiol Prot; 2016 Jun; 36(2):269-78. PubMed ID: 27089552 [TBL] [Abstract][Full Text] [Related]
4. Blood clearance and occupational exposure for Abuqbeitah M; Demir M; Uslu-Beşli L; Yeyin N; Sönmezoğlu K Radiat Environ Biophys; 2018 Mar; 57(1):55-61. PubMed ID: 29149420 [TBL] [Abstract][Full Text] [Related]
5. PSMA-Targeted Radionuclide Therapy of Metastatic Castration-Resistant Prostate Cancer with 177Lu-Labeled PSMA-617. Kratochwil C; Giesel FL; Stefanova M; Benešová M; Bronzel M; Afshar-Oromieh A; Mier W; Eder M; Kopka K; Haberkorn U J Nucl Med; 2016 Aug; 57(8):1170-6. PubMed ID: 26985056 [TBL] [Abstract][Full Text] [Related]
7. Lu-177-PSMA-617 Prostate-Specific Membrane Antigen Inhibitor Therapy in Patients with Castration-Resistant Prostate Cancer: Stability, Bio-distribution and Dosimetry. Kabasakal L; Toklu T; Yeyin N; Demirci E; Abuqbeitah M; Ocak M; Aygün A; Karayel E; Pehlivanoğlu H; Alan Selçuk N Mol Imaging Radionucl Ther; 2017 Jun; 26(2):62-68. PubMed ID: 28613198 [TBL] [Abstract][Full Text] [Related]
8. EFFECTIVE HALF-LIFE, EXCRETION AND RADIATION EXPOSURE OF 177LU-PSMA. Parlak Y; Mutevelızade G; Sezgın C; Goksoy D; Gumuser G; Sayıt E Radiat Prot Dosimetry; 2023 Jun; 199(10):1090-1095. PubMed ID: 37097774 [TBL] [Abstract][Full Text] [Related]
9. Prediction of Normal Organ Absorbed Doses for [177Lu]Lu-PSMA-617 Using [44Sc]Sc-PSMA-617 Pharmacokinetics in Patients With Metastatic Castration Resistant Prostate Carcinoma. Khawar A; Eppard E; Sinnes JP; Roesch F; Ahmadzadehfar H; Kürpig S; Meisenheimer M; Gaertner FC; Essler M; Bundschuh RA Clin Nucl Med; 2018 Jul; 43(7):486-491. PubMed ID: 29688951 [TBL] [Abstract][Full Text] [Related]
10. Pre-therapeutic dosimetry of normal organs and tissues of (177)Lu-PSMA-617 prostate-specific membrane antigen (PSMA) inhibitor in patients with castration-resistant prostate cancer. Kabasakal L; AbuQbeitah M; Aygün A; Yeyin N; Ocak M; Demirci E; Toklu T Eur J Nucl Med Mol Imaging; 2015 Dec; 42(13):1976-83. PubMed ID: 26227531 [TBL] [Abstract][Full Text] [Related]
11. Post-therapeutic dosimetry of 177Lu-DKFZ-PSMA-617 in the treatment of patients with metastatic castration-resistant prostate cancer. Yadav MP; Ballal S; Tripathi M; Damle NA; Sahoo RK; Seth A; Bal C Nucl Med Commun; 2017 Jan; 38(1):91-98. PubMed ID: 27782913 [TBL] [Abstract][Full Text] [Related]
12. Pretherapeutic 68Ga-PSMA-617 PET May Indicate the Dosimetry of 177Lu-PSMA-617 and 177Lu-EB-PSMA-617 in Main Organs and Tumor Lesions. Wang J; Zang J; Wang H; Liu Q; Li F; Lin Y; Huo L; Jacobson O; Niu G; Fan X; Zhu Z; Chen X Clin Nucl Med; 2019 Jun; 44(6):431-438. PubMed ID: 30985422 [TBL] [Abstract][Full Text] [Related]
13. Response and Tolerability of a Single Dose of 177Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer: A Multicenter Retrospective Analysis. Rahbar K; Schmidt M; Heinzel A; Eppard E; Bode A; Yordanova A; Claesener M; Ahmadzadehfar H J Nucl Med; 2016 Sep; 57(9):1334-8. PubMed ID: 27056618 [TBL] [Abstract][Full Text] [Related]
14. Dosimetry for (177)Lu-DKFZ-PSMA-617: a new radiopharmaceutical for the treatment of metastatic prostate cancer. Delker A; Fendler WP; Kratochwil C; Brunegraf A; Gosewisch A; Gildehaus FJ; Tritschler S; Stief CG; Kopka K; Haberkorn U; Bartenstein P; Böning G Eur J Nucl Med Mol Imaging; 2016 Jan; 43(1):42-51. PubMed ID: 26318602 [TBL] [Abstract][Full Text] [Related]
15. TheraP: a randomized phase 2 trial of Hofman MS; Emmett L; Violet J; Y Zhang A; Lawrence NJ; Stockler M; Francis RJ; Iravani A; Williams S; Azad A; Martin A; McJannett M; ; Davis ID BJU Int; 2019 Nov; 124 Suppl 1():5-13. PubMed ID: 31638341 [TBL] [Abstract][Full Text] [Related]
16. [44Sc]Sc-PSMA-617 Biodistribution and Dosimetry in Patients With Metastatic Castration-Resistant Prostate Carcinoma. Khawar A; Eppard E; Sinnes JP; Roesch F; Ahmadzadehfar H; Kürpig S; Meisenheimer M; Gaertner FC; Essler M; Bundschuh RA Clin Nucl Med; 2018 May; 43(5):323-330. PubMed ID: 29485430 [TBL] [Abstract][Full Text] [Related]
17. Dosimetry of Violet J; Jackson P; Ferdinandus J; Sandhu S; Akhurst T; Iravani A; Kong G; Kumar AR; Thang SP; Eu P; Scalzo M; Murphy D; Williams S; Hicks RJ; Hofman MS J Nucl Med; 2019 Apr; 60(4):517-523. PubMed ID: 30291192 [No Abstract] [Full Text] [Related]
18. Radiation Dosimetry and Biodistribution of Piron S; De Man K; Van Laeken N; D'Asseler Y; Bacher K; Kersemans K; Ost P; Decaestecker K; Deseyne P; Fonteyne V; Lumen N; Achten E; Brans B; De Vos F J Nucl Med; 2019 Dec; 60(12):1736-1742. PubMed ID: 31028165 [TBL] [Abstract][Full Text] [Related]
19. Preclinical Development of Novel PSMA-Targeting Radioligands: Modulation of Albumin-Binding Properties To Improve Prostate Cancer Therapy. Umbricht CA; Benešová M; Schibli R; Müller C Mol Pharm; 2018 Jun; 15(6):2297-2306. PubMed ID: 29684274 [TBL] [Abstract][Full Text] [Related]